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partly due to the secondary effect of being thin, and not the direct
result of the CR diet.
Finally, the small number of adherents to a CR life-style speaks
to the difficulty in depriving oneself every day of preferred type and
amounts of food. We hypothesize (5) that alternate-day calorie
restriction, in which one eats less and more than needed to maintain
body weight on alternating days, will provide the same health benefits
as daily CR; it is a much more agreeable way of living, and it appears
to have a profound effect on cardiac function (6).
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REPLY
We appreciate the views expressed by Dr. Johnson and colleagues
regarding our recent study (1) concerning caloric restriction (CR)
and diastolic function (DF). We agree that in large population
studies, diastolic dysfunction, body mass index (BMI), and adi-
posity are correlated. It would be ideal to have a BMI and
body-fat–matched control group that is healthy and not calorie
restricted. However, it is self-evident that such a control group is
not readily available. It would be extremely difficult to find healthy
individuals, other than extreme endurance athletes, who have a
BMI 20 kg/m2 who are not calorie restricted. Individuals with a
BMI 20 kg/m2 who are not endurance athletes or calorie
restricted are generally in ill-health and frail or heavy smokers.
Endurance exercise training causes major cardiovascular adapta-
tions, so athletes are also not an appropriate control group. The
control group in our study consisted of individuals typical of the
U.S. population, as 78.2% of the men and 68.1% of the women
older than 40 years are overweight or obese in the U.S. (2).
In our study (1) we provided evidence that, in humans,
long-term CR with optimal nutrition (at least 100% of the
recommended daily intake for each nutrient) results in very low
levels of inflammation, as demonstrated by low serum C-reactive
protein and tumor necrosis factor-alpha concentration, and re-
duced left ventricular stiffness, indicated by the lower model-based
image processing–derived chamber stiffness parameter k and vis-
coelastic chamber constant c. We also found that CR is associated
with low serum concentrations of transforming growth factor-beta,
a powerful pro-fibrotic molecule that plays a role in regulating the
myocardial composition of the extracellular matrix, thus potentially
having salutary effects on k and c (3).
In contrast, individuals who are very thin owing to chronic
diseases generally have elevated levels of systemic inflammation
and have diastolic dysfunction despite a low BMI (4–6). For the
group considered, long-term CR is the cause, and the coexistent
low BMI is one effect. Conversely, we are not aware of any
mechanism by which a low BMI, as an independent variable, can
improve DF. The improved DF observed is mediated by other CR
effects, such as lowering blood pressure and decreasing the levels of
inflammatory cytokines, hormones, and growth factors that may
reduce fibrosis, increase compliance, and improve cardiac effi-
ciency.
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Implications and Controversies
of Recent Hypertension Trials
Williams has written a comprehensive and thought-provoking
review of the recent hypertension literature (1). One of his major
contentions is an iteration of the hypothesis that achieving better
cardiovascular outcomes depends on more aggressive blood pres-
sure (BP) control and not on the specific choice of antihypertensive
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agents. In particular, the claim is made that the benefits of ramipril
and perindopril evidenced in the HOPE (Heart Outcomes Pre-
vention Evaluation) (2), and EUROPA (EURopean trial On
reduction of cardiac events with Perindopril in stable coronary
Artery disease) (3) trials, respectively, are due to the lower BP
levels achieved by these agents in the treated groups. However,
when a similarly decreased level of BP is achieved in the
trandolapril-treated group in the PEACE (Prevention of Events
with Angiotensin Converting Enzyme inhibition) (4) trial, no
cardiovascular outcomes benefit is observed.
Does not this dichotomy denigrate the concept that only the
achieved BP level is what matters? Do the results of these three
trials suggest that perhaps differences exist among angiotensin-
converting enzyme inhibitors beyond their additive BP effects?
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REPLY
In a previous review, I stated that the data from large-scale clinical
trials of the treatment of hypertension suggested that the main
driver of benefit from blood-pressure (BP) lowering drugs was the
BP lowering per se (1). Dr. Schwartz in his response to this review
notes that, although the HOPE (Heart Outcomes Prevention
Evaluation) (2) and EUROPA (EURopean trial On reduction of
cardiac events with Perindopril in stable coronary Artery disease)
(3) studies showed benefits of angiotensin-converting enzyme
(ACE) inhibition versus placebo in reducing cardiovascular events
in patients with cardiovascular disease, the more recent PEACE
(Prevention of Events with Angiotensin Converting Enzyme
inhibition) (4) study did not. Dr. Schwartz states that this
dichotomy might suggest within-drug-class differences, pointing
to the benefit of specific ACE inhibitors “beyond blood pressure.”
This concept is tenuous at best and could only be proven by testing
different ACE inhibitors head-to-head in the same patient popu-
lation.
The differences in outcomes when comparing the HOPE and
EUROPA trials with the PEACE trial reflect different patient
populations and differences in comcomitant medications. Com-
pared to the HOPE and EUROPA trials, the the PEACE trial
cohort was more aggressively treated with lipid-lowering drugs
(70%), antiplatelet drugs (90%), and beta-blockers (60%), and in
such an aggressively treated population it was not even possible to
show an additional benefit of the ACE inhibitor-induced BP
lowering. The message from the PEACE study was admirably
summed up by the investigators: “in a population of patients with
coronary artery disease and preserved ejection fraction who receive
intensive current standard therapy . . . , there appears to be no
evidence of cardiovascular benefit from the addition of ACE-
inhibitor therapy” (4).
With regard to treating hypertension in an endeavor to prevent
the development of fatal or nonfatal myocardial infarction (MI),
the ALLHAT (Antihypertensive and Lipid Lowering treatment
to prevent Heart Attack Trial) study tested this hypothesis and
failed to show an advantage of ACE inhibition (5). Moreover, the
more recent CAMELOT (Comparison of Amlodipine vs. Enalapril
to Limit Occurrences of Thrombosis) study also failed to show an
advantage of ACE inhibition over the comparator, a calcium
channel blocker (CCB) in patients with angiographically proven
coronary disease (6). Finally, meta-analyses of hypertension trials
have consistently failed to show an advantage of ACE inhibitor-
based therapy over other classes of BP lowering therapy in the
prevention of MI (1).
I concede that on the basis of our recent data from the CAFE
(Conduit Artery Function Evaluation) study, it is possible to go
beyond brachial BP, depending on the choice of the BP-lowering
agent (7). In the CAFE study we showed that beta-blocker 
thiazide-based therapy was less effective at lowering central aortic
pressure when compared to a CCB  ACE inhibitor-based
treatment, despite similar effects on brachial BPs. Thus, it is
plausible that brachial BP measurements underestimated the benefi-
cial effects of ACE inhibition on central aortic BPs in the HOPE
and EUROPA trials. However, even then it is still pressure and
hemodynamics and not mysterious biology that explain the benefit
of the drugs in these trials.
It is surely beyond dispute that the most effective way to “go
beyond blood pressure” to prevent MI in patients with hyperten-
sion at high risk of cardiovascular disease is to add a statin to their
therapy (1). No amount of ACE inhibition will compete with this,
no matter what clothes the emperor wears—indeed, on the basis of
evidence alone, with regard to ACE inhibition and the prevention
of MI by drug-specific effects, the emperor has no clothes!
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